Get the Stockscreener App
0.45
71.70%
-1.14
After Hours:
.42
-0.03
-6.67%
Reshape Lifesciences Inc stock is traded at $0.45, with a volume of 74.04M.
It is down -71.70% in the last 24 hours and down -56.31% over the past month.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
See More
Previous Close:
$1.59
Open:
$0.6443
24h Volume:
74.04M
Relative Volume:
12.56
Market Cap:
$5.26M
Revenue:
$9.81M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.0116
EPS:
-38.77
Net Cash Flow:
$-17.45M
1W Performance:
-4.72%
1M Performance:
-56.31%
6M Performance:
-91.74%
1Y Performance:
-95.40%
1-Day Range:
$0.4282
$0.7018
1-Week Range:
$0.3445
$3.05
52-Week Range:
$0.3445
$29.00
Reshape Lifesciences Inc Stock (RSLS) Company Profile
Name
Reshape Lifesciences Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare RSLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
0.45 | 5.26M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
131.93 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
377.46 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.86 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.05 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Reshape Lifesciences Inc Stock (RSLS) Latest News
ReShape Lifesciences shareholders approve key proposals By Investing.com - Investing.com Australia
Nasdaq Tumbles 100 Points; UniFirst Posts Upbeat Earnings - Benzinga
ReShape Lifesciences shareholders approve key proposals - Investing.com
Stock Market News For Apr 2, 2025 - Yahoo Finance
ReShape Lifesciences Delays Yearly Report Filing - TipRanks
Global Bariatric Surgeries Market to Hit USD 27.64 Billion - GlobeNewswire
Dow Dips Over 400 Points; ISM Manufacturing PMI Falls In March - Benzinga
Sands Capital Select Growth Fund Sold Edwards Lifesciences Corporation (EW) For Better Opportunities - Yahoo Finance
Nueva Network Launches Que-Onnda Radio in Washington DC & Boston - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Frazier Life Sciences Welcomes Chris Aakre as Principal of Company Creation - Yahoo Finance
Why XPeng Inc. (XPEV) Went Up On Monday? - Yahoo Finance
Why Mr. Cooper Group Inc. (COOP) Went Up On Monday? - Yahoo Finance
WELL HEALTH TECHNOLOGIES CORP. EARLY WARNING NEWS RELEASE - Yahoo Finance
Analysts at Cantor, formerly headed by Lutnick, call for Kennedy's dismissal - Yahoo Finance
Lytus Technologies Adjusts Market Strategy and Transition to OTC Markets - Yahoo Finance
Novvia Group Acquires MegaChem - Yahoo Finance
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
Bio-Techne Opens New Customer Experience Centre in Germany - Yahoo Finance
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
Investors Heavily Search Occidental Petroleum Corporation (OXY): Here is What You Need to Know - Yahoo Finance
Pearson Expands Professional Learning Capabilities with New Skilling Partner Program - Yahoo Finance
The legal problems facing a new Trump TikTok rescue — and why they may not matter - Yahoo Finance
Is Palantir Technologies Inc. (NASDAQ:PLTR) The Best Stock to Buy and Hold for 2 Years? - Yahoo Finance
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531 - Yahoo Finance
Duchesnay Pharmaceutical Group recognized for commitment to well-being of its employees as winner of 2025 Healthiest Workplace Award - Yahoo Finance
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? - Yahoo Finance
RSLS stock touches 52-week low at $0.49 amid sharp annual decline - Investing.com Australia
RSLS stock touches 52-week low at $0.49 amid sharp annual decline By Investing.com - Investing.com South Africa
US jet fuel imports surge as Nigeria's Dangote refinery pushes barrels west - Yahoo Finance
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders - GlobeNewswire Inc.
Maravai Lifesciences price target lowered to $5 from $10 at Stifel - Yahoo Finance
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc.RSLS - Business Wire
ReShape Lifesciences Faces Board Resignation Challenge - TipRanks
RSLS stock touches 52-week low at $0.61 amid market challenges By Investing.com - Investing.com South Africa
RSLS stock touches 52-week low at $0.61 amid market challenges - Investing.com India
Pre-market Movers: REVB, QSI, EYEN, NAOV ... - RTTNews
REDFIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Redfin CorporationRDFN - Business Wire
ENDO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Endo, Inc.NDOI - Business Wire
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial - Yahoo Finance
First national perception survey of Food is Medicine programs shows strong public support - EurekAlert!
Ratio Analysis: Unpacking ReShape Lifesciences Inc (RSLS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Grow - Asianet Newsable
ReShape Lifesciences® Receives Notice of Allowance for Vagus Nerve Modulation Patent Aimed at Improving Glycemic Control - Nasdaq
ReShape Lifesciences® Receives Notice of Allowance for U.S. - GlobeNewswire
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology - Yahoo
ReShape Lifesciences Patents Breakthrough Diabetes Neuromodulation System - Stock Titan
ReShape Lifesciences, Inc. to Host Earnings Call - ACCESS Newswire
RSLS stock touches 52-week low at $0.87 amid market challenges - Investing.com Canada
RSLS stock touches 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa
Reshape Lifesciences Inc Stock (RSLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):